What laboratory tests are used to monitor or detect fibrinolysis?

Laboratory Tests for Monitoring and Detecting Fibrinolysis

The most clinically relevant tests for monitoring fibrinolysis are D-dimers and fibrinogen in routine practice, while specialized settings utilize viscoelastic testing (ROTEM/TEG), euglobulin clot lysis assays, and specific factor measurements depending on whether you're assessing hyperfibrinolysis, hypofibrinolysis, or individual fibrinolytic components 1.

Clinical Laboratory Tests (Routine Practice)

The 2023 ISTH guidelines emphasize that laboratory analyses in clinical settings most commonly rely on select biomarkers in plasma samples, most notably D-dimers and fibrinogen 1. These are the workhorses of fibrinolysis detection because:

• D-dimers/FDPs (Fibrin Degradation Products): Measured by ELISA, these are clinically used to determine ongoing thrombosis/fibrinolysis in patients, though they lack sensitivity and standardization for global comparison 1
• Fibrinogen levels: Provides baseline assessment of substrate availability for fibrinolysis 1

Important caveat: D-dimers have a long half-life (>12 hours in healthy individuals) and reflect past fibrinolytic activity rather than real-time fibrinolysis 1. This makes interpretation challenging in acute settings.

Point-of-Care and Specialized Testing

Viscoelastic Methods (ROTEM/TEG)

These are currently the only methods that can detect severe fibrinolysis in real-time 2. They provide:

• Whole blood analysis to determine coagulopathy and hypo/hyperfibrinolysis 1
• Kinetic assessment incorporating cellular elements (platelets, neutrophils, red blood cells) 1
• Particularly valuable in trauma, cardiac surgery, liver transplantation, and critically-ill patients 1

Critical limitation: Viscoelastic testing requires careful interpretation as results can be confounded by various factors, and there are conflicting reports about what these tests actually detect and measure 1.

Comprehensive Fibrinolysis Assessment Panel

When detailed fibrinolytic characterization is needed (research or specialized clinical scenarios), the following tests are available 1:

Overall Fibrinolytic Activity

• Euglobulin Clot Lysis Time (ECLT): Kinetic assay measuring endogenous tPA activity; useful to identify elevated PAI-1
• Clot Lysis Assays (PA-CLT): Measures overall fibrinolytic potential with or without exogenous tPA

Individual Fibrinolytic Components

Plasminogen System:

• ELISA for total plasminogen levels
• Functional assays for plasminogen activity
• Plasmin generation assays (kinetic) - quantify rate of active plasmin generation over time

Tissue Plasminogen Activator (tPA):

• ELISA for total tPA (free tPA + tPA/PAI-1 complex)
• ELISA for PAI-1-free tPA
• Chromogenic/fluorogenic assays for functional tPA activity

Urokinase Plasminogen Activator (uPA):

• ELISA for total uPA
• Chromogenic activity assays (note: TXA presence may interfere)

Inhibitors:

• PAI-1: ELISA for total levels (active, latent, complexed forms); kinetic assays for functional PAI-1
• Alpha-2-antiplasmin (α2AP): ELISA for total levels; kinetic assays inferring functional levels
• TAFI (Thrombin-Activatable Fibrinolysis Inhibitor): ELISA for TAFI and its products; TAFIa-specific assays

Enzyme-Inhibitor Complexes:

• tPA:PAI-1 complex (ELISA)
• Plasmin:α2AP complex (PAP) - ELISA specifically measuring the complex 1

Algorithmic Approach to Test Selection

For acute bleeding/hyperfibrinolysis (trauma, surgery, postpartum):

1. First-line: Viscoelastic testing (ROTEM/TEG) - only method detecting severe acute fibrinolysis 2
2. Adjunct: Fibrinogen, D-dimer, PAP complex

For thrombotic risk assessment/hypofibrinolysis:

1. D-dimer (elevated suggests ongoing thrombosis)
2. PAI-1 levels (elevated associated with thrombotic risk)
3. TAFI levels (elevated may indicate hypofibrinolysis)
4. Clot lysis assays for functional assessment

For mechanistic investigation:

• Comprehensive panel including individual factor antigens and activities
• Euglobulin clot lysis assays
• Plasmin generation assays

Critical Pitfalls to Avoid

1. Over-interpretation of antigen levels: Total protein concentration doesn't indicate functional activity. A patient may have normal plasminogen antigen but dysfunctional protein 1

2. Exogenous activation artifacts: Many functional tests use exogenous activators (thrombin, tissue factor, tPA) that create maximal artificial fibrinolytic activity rather than measuring endogenous potential 1

3. Timing matters: PAP complex has a half-life exceeding 12 hours, so elevated levels may reflect past rather than current fibrinolysis 1

4. Lack of standardization: Different assays and reagents produce non-comparable results, particularly for D-dimer 1

5. Context-dependent interpretation: The same test result means different things in different clinical scenarios (trauma vs. malignancy vs. pregnancy) 1

The 2023 ISTH guidelines emphasize that global point-of-care testing to identify fibrinolytic potential is not widely implemented, and choosing appropriate assays requires understanding both the clinical question being asked and the limitations of each method 1.